Dr. Jaymie Sawyer, Vice President of R&D, Transitions to Lead Scientific Advisory Committee

TORONTO, July 13, 2017 /CNW/ - SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD; OTCQX: SQIDF), today announced that following a personal decision to return to the USA Dr. Jaymie Sawyer has resigned her full-time responsibilities as Vice President of R&D of the Company, effective 24 July 2017.  SQI is excited to also announce that Dr. Sawyer has been engaged as a Scientific Advisor and will serve on SQI's Scientific Advisory Committee to provide on-going scientific expertise to the Company's research and development efforts.

During her seven years as head of R&D, Dr. Sawyer has made valuable contributions to the Company's product development programs and has built a strong and expert team of scientists to continue executing the Company's product development strategy.  The Company has launched a search for Dr. Sawyer's replacement and expects to fill the R&D leadership position in the coming weeks. 

"We want to thank Dr. Sawyer for the strong leadership she has shown in our R&D initiatives and we very much look forward to working closely with her in her new capacity" said Andrew Morris, CEO of SQI Diagnostics.

About SQI Diagnostics
SQI Diagnostics is a life sciences and diagnostics company that develops clinical grade multiplexed microarray and molecular assays run on its automated instrumentation for the pharmaceutical research, animal health, and clinical diagnostics markets. SQI develops custom research and diagnostic assays that are multiplexed; meaning the simplification, consolidation and automation of many individual tests into one. This increases sample throughput, reduces time, cost and chance for human error, and provides excellent data quality. For more information, please visit sqidiagnostics.com.

Investor Relations Contacts:


Chief Executive Officer 

Vice President, Finance and Administration

Andrew Morris 

Patricia Lie

416.674.9500 ext. 229  

416.674.9500 ext. 277

amorris@sqidiagnostics.com 

plie@sqidiagnostics.com

 

Forward-looking Statements
This press release contains certain statements including, without limitation, the words "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect", "believe", "in the process", "benefits", "leading to", "position" "possible", "is subject to" and other similar expressions which may constitute "forward-looking statements" within the meaning of applicable securities laws. Forward-looking statements reflect the Company's current expectations and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated.  Readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements involve risks and uncertainties including, but not limited to: our ability to market and sell our products including our novel multiplexing technologies and detection platforms; our ability to maintain any technical or product advantages; the success of our Diagnostic Tools and Services business and our intent to build near-term revenue streams from this business; the successful regulatory filing and receipt of regulatory approvals for our later stage quantitative diagnostic consumable kits; adverse changes in general economic conditions; international risk and currency exchange fluctuations; competitor activity; technology changes; regulatory approvals and the impact of healthcare reform legislation; and, SQI's ability to raise additional funds in the future.

Such statements, risks and uncertainties are detailed in the Company's ongoing filings with the securities regulatory authorities, and are available to the public at www.sedar.com. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable securities laws.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE SQI Diagnostics Inc.

For further information: Investor Relations Contacts: Chief Executive Officer, Andrew Morris, 416.674.9500 ext. 229, amorris@sqidiagnostics.com; Vice President, Finance and Administration, Patricia Lie, 416.674.9500 ext. 277, plie@sqidiagnostics.com

RELATED LINKS
www.sqidiagnostics.com

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890